Livagen

Livagen is the tetrapeptide Lys-Glu-Asp-Ala, catalogued by the US National Library of Medicine as lysyl-glutamyl-aspartylalanine and shortened to KEDA. Retailers file it under liver support.

Its most-cited paper studied lymphocytes from elderly donors, run by a Tbilisi cytogenetics group working with Khavinson's laboratory — the collaboration behind most of what exists on this peptide, and one interested in chromosome structure rather than hepatology.

In those lymphocytes KEDA was reported to activate ribosomal genes, decondense pericentromeric heterochromatin and release genes compacted with age ( Khavinson, Lezhava et al., Bull Exp Biol Med 2002;134(4):389-92). The reasoning runs: chromatin loosens, silenced genes resume transcription, ageing cells behave younger. It is a coherent story told from microscope images of chromosome spreads.

Hepatitis, alcohol-related liver disease, steatohepatitis and cirrhosis are managed with treatments that have outcome data; KEDA appears in none of those pathways. One Russian-language review reports hepato- and immunoprotective effects for KEDA and a liver polypeptide complex across animal models of acute hepatitis, chronic hepatitis and cirrhosis ( Kuznik et al., Adv Gerontol 2020;33(1):159-64). A review in a specialty gerontology journal, by the people who developed the compound, is where the liver claim begins and ends.

The general S0 provision does apply, covering substances no government health authority has approved for human therapeutic use. Athletes under testing jurisdiction should put the question to their anti-doping organisation in writing.

There is no published toxicology for KEDA and no clinical tolerability report. Given the marketing, one point deserves emphasis: the liver clears most of what enters the body, so an unregulated injectable of uncertain purity is a plausible source of hepatic injury rather than protection against it.

No absorption, distribution, half-life or clearance data exist for KEDA in humans, so there is no rational basis for a dose and this page proposes none.

Sold as a lyophilised powder. The 2020 review pairs it with Ventvil, a polypeptide complex extracted from liver tissue — worth noting because tissue extracts and synthetic tetrapeptides are different categories sharing a shelf.

Fewer than twenty PubMed records name Livagen, spread across Bulletin of Experimental Biology and Medicine, Georgian Medical News and Advances in Gerontology, most in Russian. The recurring authors are Khavinson, Lezhava and Dzhokhadze; the recurring method is chromatin staining. No group outside that network has published a replication, and no clinical study of any design exists.

For deeper dives on this peptide, see:

• Livagen benefits and areas of interest
• Livagen side effects and safety context
• Livagen dosing concepts (educational)
• Livagen research and evidence overview

Has Livagen been tested in people with liver disease? No. Hepatoprotection reports come from animal models summarised by the compound's own developers in Russian-language gerontology journals.

How does Livagen differ from Prostamax and Pancragen? They are the same first three residues with a different fourth: KEDA for Livagen, KEDP for Prostamax, KEDW for Pancragen. That final amino acid is the entire basis for assigning them to liver, prostate and pancreas respectively — an assignment asserted by the theory, not established by comparative experiment.

Why is this evidence base considered weak? It is small, old, published mainly in one language in low-circulation journals, authored repeatedly by the same collaborators, and built on surrogate markers rather than clinical outcomes. Any one of those is a caveat; together they mean the findings have never been tested.

Is it approved anywhere as a medicine? It carries no marketing authorisation from the FDA, EMA or MHRA and is not a licensed hepatology treatment in any jurisdiction we can document.